Weather forecast

CorMedix (CRMD) stock forecast

Clear blue sky

Buy

Score 80/100 · Confidence 85%

The outlook is bright — conditions favour stepping in.

Weighed fromlive price action

Why this call

Explosive Growth at a Low Price

The stock has been in a clear uptrend since hitting lows a month ago.

The company's very low valuation may continue to attract new buyers.

Underlying business growth and profitability are exceptionally strong.

Where it's headed

CorMedix price targets

As of Jun 20, 2026, Tickerday rates CorMedix (CRMD) a Buy, score 80/100, with 85% confidence. Each target is measured from $8.67, the price that day.

Next week

$8.70

+0.3% from $8.67

Near-term momentum has stalled after a recent run-up, suggesting the price may stay in a tight range this week.

Next month

$9.50

+9.6% from $8.67

A strong one-month uptrend, backed by powerful fundamentals, could continue to push the stock higher.

Next year

$14.70

+69.5% from $8.67

The company's powerful growth, high profitability, and very low valuation present a compelling long-term case if it can sustain its performance.

Share this forecastXRedditWhatsApp

Under the hood

What the engine weighed

Six factors, scored 0–100 from live market and financial data — the same read Wall Street does, minus the jargon.

80Overall score
Valuation
95

The stock's P/E ratio of 3.8 is exceptionally low, suggesting it's very cheap relative to earnings.

Growth
98

Recent revenue growth has been explosive, expanding by over 380%.

Profitability
95

The company is highly profitable, with an impressive net margin of over 45%.

Momentum
60

The stock has a positive one-month trend but is still well below its highs from the past year.

Fin. health
85

With a low debt-to-equity ratio of 0.33, the company's balance sheet appears solid.

Sentiment
50

There is no significant recent news to suggest a strong positive or negative market mood.

Key numbers

as of Jun 20, 2026

Size and price

Growth and profit

Risk and payout

The argument

Both sides of the sky

Every call has a case against it. Here's the honest version of both.

The bull case

  • The company's valuation looks very attractive, with a price-to-earnings ratio of just 3.8.
  • Revenue has grown at an explosive rate of over 380% in the last year.
  • It operates with extremely high profit margins (45.3% net margin) and has low debt.

The bear case

  • The stock price is down significantly from its 52-week high of $17, indicating a weak long-term trend despite a recent recovery.
  • As a small pharmaceutical company, future success can depend heavily on a small number of products.
  • The stock is historically more volatile than the broader market, as shown by its Beta of 1.50.

FAQ

Good questions

Tickerday's read of CorMedix as of Jun 20, 2026: educational analysis, the same for everyone, not financial advice.

Most tools hand you the data.
Tickerday hands you the answer.

Now try yours

What about your stocks?

You just read CorMedix. Type a company you own and get its call, and the why, in seconds. First one free, no account needed.

SearchApple

The receipts

Called it. Then it happened.

Real calls from the Tickerday engine, each one graded against the real price a month later.

Palantir Technologies Inc.

+52.3%

✓Called it

We said Buy at $122.33 on Jul 30. A month later the price was $186.29.

Graded Aug 28 at the closing price

Today's prices

Weather alerts

We'll watch the weather.You enjoy the day.

Save a stock to your Almanac. We'll track its forecast and let you know when the outlook changes.

Your Almanac

Watching 4 stocks

CRMD

CorMedix

Buy

AAPL

Apple

Buy

MSFT

Microsoft

Buy

TSLA

Tesla

Sell

9:41

Thursday, October 16

9:41

Nothing to chase. Nothing to refresh.

Sunny under an umbrella

One blind call costs more
than a year of Tickerday.

Pricing

Start free, right here

Your first analysis is free, no account needed. Tickerday+ takes it from there.

Tickerday+

Pro

Built for fast clarity.

  • Clear buy / hold / sell-style insights
  • Key risks and opportunities
  • Focused market analysis
  • 40 priority credits every month
$9/mo

Billed monthly · ≈ $0.30/day

Tickerday+

Most popular

Premium

The full why, explained.

  • Expanded analysis & learning depth
  • Interactive explanations & breakdowns
  • Tap to understand key metrics & terms
  • 100 priority credits every month
$228 (was)$169/yrSAVE 26%

Billed yearly · ≈ $14.08/mo≈ $0.46/day

Cancel anytime.

Sunny, Tickerday's mascot, fast asleep under the stars

Get the full picture

That took thirty seconds. Now imagine every stock you own.

You just understood CRMD without reading a single chart. The Tickerday app does this for your whole watchlist — today's read whenever you want it, the full thesis, bull and bear scenarios with their odds — and wakes you the moment the weather turns.

One plain answer for every stock — Buy, Hold, or Sell

The full picture in seconds — thesis, targets & scenarios

Sleep easy — we watch the market and wake you if it turns

Free to download the day it lands — the web desk is open now

More forecasts

More lists